BCHE: Cholinesterase
Esterase with broad substrate specificity.
- Drugs that act on it: 1
- Approved: 1
- In phases 1 to 3: 0
- Sponsors: 0
Who is on it, and how far along
Every drug ChEMBL records acting on BCHE, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| PropanididWithdrawn | Approved | — | Small molecule | InhibitorButyrylcholinesterase inhibitor | 0 |
- Butyrylcholinesterase deficiency0.81
- Alzheimer disease0.63
- Parkinson disease0.61
- Dementia0.61
- Mathematical ability0.36
- Delirium0.34
- Vascular dementia0.33
- Brain injury0.33
- Auditory system disorder0.31
- Response to stimulus0.29
- Adverse effect0.29
- Pneumococcal pneumonia0.29
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1914, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P06276, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets